

## ORIGINAL ARTICLE

# Noninfectious Hospital Adverse Events Decline After Elimination of Contact Precautions for MRSA and VRE

Elise M. Martin, MD, MS;<sup>1</sup> Brandy Bryant, MPH;<sup>2</sup> Tristan R. Grogan, MS;<sup>3</sup> Zachary A. Rubin, MD;<sup>1</sup> Dana L. Russell, MPH;<sup>4</sup> David Elashoff, PhD;<sup>3</sup> Daniel Z. Uslan, MD, MBA, FIDSA, FSHEA<sup>1</sup>

**OBJECTIVE.** To evaluate the impact of discontinuing routine contact precautions (CP) for endemic methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE) on hospital adverse events.

**DESIGN.** Retrospective, nonrandomized, observational, quasi-experimental study.

**SETTING.** Academic medical center with single-occupancy rooms.

**PARTICIPANTS.** Inpatients.

**METHODS.** We compared hospital reportable adverse events 1 year before and 1 year after discontinuation of routine CP for endemic MRSA and VRE (preintervention and postintervention periods, respectively). Throughout the preintervention period, daily chlorhexidine gluconate bathing was expanded to nearly all inpatients. Chart reviews were performed to identify which patients and events were associated with CP for MRSA/VRE in the preintervention period as well as the patients that would have met prior criteria for MRSA/VRE CP but were not isolated in the postintervention period. Adverse events during the 2 periods were compared using segmented and mixed-effects Poisson regression models.

**RESULTS.** There were 24,732 admissions in the preintervention period and 25,536 in the postintervention period. Noninfectious adverse events (ie, postoperative respiratory failure, hemorrhage/hematoma, thrombosis, wound dehiscence, pressure ulcers, and falls or trauma) decreased by 19% (12.3 to 10.0 per 1,000 admissions,  $P = .022$ ) from the preintervention to the postintervention period. There was no significant difference in the rate of infectious adverse events after CP discontinuation (20.7 to 19.4 per 1,000 admissions,  $P = .33$ ). Patients with MRSA/VRE showed the largest reduction in noninfectious adverse events after CP discontinuation, with a 72% reduction (21.4 to 6.08 per 1,000 MRSA/VRE admissions;  $P < .001$ ).

**CONCLUSION.** After discontinuing routine CP for endemic MRSA/VRE, the rate of noninfectious adverse events declined, especially in patients who no longer required isolation. This suggests that elimination of CP may substantially reduce noninfectious adverse events.

*Infect Control Hosp Epidemiol* 2018;39:788–796

Although both the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America still recommend contact precautions (CP) to decrease the transmission of methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE) in acute-care hospitals, recent data have indicated a need to question whether this should remain the standard of care.<sup>1–8</sup>

Several institutions have eliminated routine CP for MRSA and VRE; instead, they solely employ horizontal infection prevention strategies to decrease spread of resistant organisms, such as improved hand hygiene and targeted or universal decolonization with products like chlorhexidine gluconate

(CHG).<sup>3,6–8</sup> Three studies specifically looking at infectious outcomes of removing routine CP have reported no increase in infectious complications, such as device-associated infections, MRSA acquisitions, MRSA environmental contamination, and healthcare-associated infections with MRSA and/or VRE.<sup>6–8</sup> Although some data support CP in combination with other horizontal strategies, data on gowns and gloves alone are lacking.<sup>3,9–20</sup>

Multiple studies have shown potential patient harms associated with the use of CP, including increased preventable adverse events, such as falls, pressure ulcers, medication administration errors, and deep vein thrombosis.<sup>21–23</sup> CP have

**Affiliations:** 1. Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California; 2. Department of Quality Management, UCLA Health, Los Angeles, California; 3. Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California; 4. Clinical Epidemiology and Infection Prevention, UCLA Health, Los Angeles, California.

**PREVIOUS PRESENTATION.** The data in this manuscript were presented in part (Poster no. 616) at the SHEA Spring 2016 conference: Science Guiding Prevention, in Atlanta, Georgia, on May 20, 2016.

Received January 8, 2018; accepted March 10, 2018; electronically published May 10, 2018

© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2018/3907-0004. DOI: 10.1017/ice.2018.93

also been associated with fewer healthcare provider visits, shorter healthcare provider contact time, and lack of appropriate documentation.<sup>21,24–28</sup> These patients can experience delays in admission from the emergency room, delays in discharge to skilled nursing facilities, and increased hospital length of stay.<sup>21,29–32</sup> Patients under CP also exhibited increased anxiety, increased depression, and lower satisfaction compared to patients not in isolation.<sup>21,33,34</sup> Although the patient harms data are concerning, newer studies have revealed conflicting results. Another 2 recent studies found no increase in adverse events in patients on CP; such results have fostered ongoing uncertainty about the impact of CP on hospital adverse events.<sup>35,36</sup>

The University of California–Los Angeles (UCLA) Health eliminated routine CP for endemic MRSA and VRE in 2014. Researchers there published a quasi-experimental study evaluating the impact of discontinuing CP for these organisms on healthcare-associated infections with MRSA and VRE.<sup>6</sup> Endemic was defined as a nonoutbreak setting, with stable baseline rates of MRSA (0.43 laboratory-identified clinical cultures per 100 admissions) and VRE (0.62 clinical cultures per 100 admissions). The study showed no increase in MRSA or VRE laboratory-identified clinical cultures, colonization, or rates of drug resistance, as well as significant savings in healthcare worker time and \$643,776 per year on materials.

The purpose of the present study was to determine the impact of discontinuing routine CP for endemic MRSA and VRE on infectious and noninfectious adverse events.

## METHODS

### Hospital Setting

This study was conducted at the Ronald Reagan UCLA Medical Center (RRUCLA), a 540-bed, tertiary-care, academic hospital with 154 intensive care unit (ICU) beds, a large transplant population, and a level 1 trauma center. All rooms are single occupancy and have alcohol-based hand rubs and sinks for hand hygiene. Contact precaution (CP) rooms are additionally equipped with signage, isolation gowns, and gloves.

### Study Design

We performed a retrospective, nonrandomized, observational, quasi-experimental study comparing infectious and noninfectious adverse events at RRUCLA. The preintervention period was from June 1, 2013, to May 31, 2014, and the postintervention period was from July 1, 2014, to June 30, 2015. Routine CP were discontinued on July 1, 2014 for endemic MRSA and VRE, including infection, colonization, and prior history of MRSA and/or VRE.<sup>6</sup> Chlorhexidine gluconate (CHG) bathing had been required in ICUs since 2012, except in the neonatal ICU. Daily 2% CHG bathing was expanded throughout the preintervention period to eventually

include all patients by May 2014, except neonates and perinatal patients. Compliance with CHG bathing was documented in the medical record and was regularly audited. Adverse events data were collected for both periods. The calendar month of June 2014 was excluded from evaluation given that the new isolation policy changes were implemented during this month and CP was less consistent, making the data from this month less reliable.

Adverse event data were collected retrospectively from 4 database sources: the Center for Medicare & Medicaid Service Hospital Acquired Conditions (HAC), Agency for Healthcare Research and Quality Patient Safety Indicators (PSI), National Healthcare Safety Network (NHSN), and the internal UCLA adverse-events reporting system.<sup>37–39</sup> Prior to data extraction and analysis, our team reviewed all routinely reported adverse event categories in these databases and selected event types most likely to be impacted by lack of contact with healthcare providers. Adverse events deemed independent of provider contact time were excluded (Table 1). Noninfectious adverse events included falls and trauma, postoperative hemorrhage and/or hematoma, postoperative respiratory failure, wound dehiscence, pressure ulcer, and pulmonary embolism (PE)

TABLE 1. Sources of Adverse Event Data<sup>a</sup>

Outcome Data	Event Reporting System		
	NHSN	HAC	PSI
Infectious Adverse Events	X		
Hospital-onset <i>Clostridium difficile</i> infections	X		
Catheter-associated urinary tract infections	X		
Central-line-associated bloodstream infections	X		
Postoperative sepsis			X
Surgical site infections	X		
Ventilator-associated events	X		
Noninfectious Adverse Events			
Falls and trauma		X	
Pressure ulcers		X	X
Postoperative respiratory failure			X
Wound dehiscence			X
Postoperative hemorrhage and/or hematoma			X
Pulmonary emboli and deep vein thrombosis		X	X

NOTE. NHSN, National Healthcare Safety Network; HAC, hospital-acquired conditions; PSI, patient safety indicators.

<sup>a</sup>An internal reporting system checked for all listed events if not otherwise reported to one of these agencies. Given the differences in reporting definitions, all events found in each system were included. If data could be collected from >1 source, data from all sources were included and duplicates of the same event were removed. Excluded conditions: accidental puncture or laceration, air embolism, birth trauma, blood incompatibility, death rate among surgical inpatients with serious treatable complications, death rate in low-mortality diagnosis related groups, foreign object retained after surgery, iatrogenic pneumothorax, manifestations of poor glycemic control, obstetric trauma rate, postoperative acute kidney injury requiring dialysis rate, transfusion reaction rate.

and/or DVT. Infectious adverse events included hospital onset *Clostridium difficile* infection (CDI), catheter-associated urinary tract infection (CAUTI), central-line-associated bloodstream infection (CLABSI), postoperative sepsis, surgical site infection (SSI), and ventilator-associated pneumonia (VAP). Table 1 describes the source of each adverse event. If data could be collected from >1 source, the data were aggregated, and duplicate events were removed. Adverse events were defined and collected according to the standardized definitions provided by each agency prior to the study for regulatory reporting purposes by hospital employees. The date used for inclusion in either the preintervention or postintervention period was the exact event date entered into the database, or if not available, the date of discharge. There were no major changes in collection methodology or reporting during the study period, except CAUTI which excluded yeast and colony counts less than 100,000 in 2015.

This study was deemed exempt by the UCLA Institutional Review Board as nonhuman subject research given that the data were collected for quality improvement purposes prior to the study.

Each adverse event was associated with an isolation type, either “MRSA and/or VRE,” “other isolation” (ie, multidrug-resistant *Acinetobacter*, carbapenem-resistant Enterobacteriaceae, aminoglycoside-resistant *Pseudomonas*, and CDI), “combination” (ie, other isolation + MRSA/VRE), and “no isolation.” Additional isolation statuses, including droplet, airborne, or syndromic indications for isolation, were not evaluated in this study. The data regarding isolation status were collected from the electronic health record. In the post-intervention period, patients were not isolated for MRSA/VRE, so they did not have an electronic isolation alert. Instead, investigators applied previous criteria for MRSA/VRE isolation (history of MRSA/VRE alerts in the electronic

health record in the previous 5 years, positive MRSA/VRE screening culture or clinical culture in the previous 2 years) to determine who would have previously qualified for isolation. A chart review was performed to collect demographic and hospitalization-specific data for patients with an adverse event.

### Statistical Analysis

Patient characteristics for those who experienced infectious or noninfectious adverse events were summarized preintervention and postintervention (ie, before and after CP discontinuation) using means for continuous variables and frequencies (%) for categorical variables (Table 2).

We assessed the effect of a policy change in which CP was discontinued on adverse events using 2 approaches. First, we tested for overall differences in adverse event rates preintervention and postintervention using Poisson regression models by including only a preintervention and postintervention predictor variable (Tables 3 and 4). We then ran longitudinal Poisson models considering monthly trends in adverse event incidence to test for immediate effects of the intervention as well as compute slope differences preintervention and postintervention. This analysis was carried out using interrupted time series analysis (segmented regression analysis) as described by Wagner et al.<sup>40</sup> Specifically, we used Poisson mixed-effects models with the outcome as the adverse event of interest and predictor terms for the baseline trend, level change after the intervention, trend change after intervention, and a patient random effect. The rates are reported per 1,000 admissions unless otherwise noted. Statistical summaries (incidence rate ratios, 95% confidence intervals, *P* values) and figures from these models are presented in Figures 1 and 2 and Tables 3 and 4.

TABLE 2. Demographics of Patients With an Adverse Event

Variable	Infectious Adverse Events		Noninfectious Adverse Events	
	Preintervention (n = 523)	Postintervention (n = 505)	Preintervention (n = 312)	Postintervention (n = 260)
Age, y (SD)	52 (±22)	54 (±21)	56 (±20)	57 (±18)
Male, %	45	49	63	59
Length of stay, d (SD)	53 (±100)	44 (±83)	39 (±52)	39 (±71)
Insurance, %				
Medicare	38	35	45	44
MediCal	20	19	25	25
ICU	43	38	40	45
Transplant	20	20	27	20
Hospital primary team, %				
Medicine	29	31	13	12
Surgery	60	58	82	83
Other	11	10	4	5
CCI (SD)	2.8 (±2.0)	3.0 (±2.1)	2.8 (±1.9)	2.9 (±2.1)

NOTE. SD, standard deviation; MediCal, California Medicaid; CCI, Charlson comorbidity index.

TABLE 3. Change in the Rate of Infectious and Noninfectious Adverse Events After the Policy Change

Adverse Event	Preintervention Rate (Before n = 24,732 admissions) <sup>a</sup>	Postintervention Rate (After n = 25,536 admissions) <sup>a</sup>	P Value <sup>b</sup>	Slope Change (95% CI) <sup>c</sup>	P Value <sup>b</sup>
Noninfectious adverse events	12.3	10.0	<b>.02</b>	0.94 (0.90–0.99)	<b>.028</b>
Falls and trauma	1.1	0.70	.16	0.90 (0.76–1.06)	.21
Hemorrhage and/or hematoma	5.5	4.5	.12	0.89 (0.83–0.96)	<b>.004</b>
Postoperative respiratory failure	1.42	1.80	.28	0.95 (0.83–1.09)	.48
Wound dehiscence	0.1	0.2	.51	0.94 (0.59–1.51)	.80
Pressure ulcer	1.2	0.7	.053	0.96 (0.81–1.14)	.64
Pulmonary embolism or deep vein thrombosis	3.0	2.2	.08	1.05 (0.95–1.16)	.36
Infectious adverse events	20.7	19.4	.33	0.99 (0.95–1.02)	.43
Hospital-onset <i>C. difficile</i>	6.5	6.5	.96	1.02 (0.96–1.08)	.58
Catheter-associated urinary tract infection	4.0	3.4	.30	0.95 (0.88–1.03)	.23
Central-line-associated bloodstream infection	4.4	4.6	.78	1.02 (0.94–1.10)	.68
Postoperative sepsis	0.4	0.6	.38	1.15 (0.93–1.43)	.20
Surgical site infection	5.2	4.0	<b>.03</b>	0.89 (0.83–0.96)	<b>.002</b>
Ventilator-associated pneumonia	0.2	0.4	.17	1.34 (0.99–1.83)	.06

<sup>a</sup>Rate per 1,000 admissions.

<sup>b</sup>Bold values are statistically significant.

<sup>c</sup>Slope change is the incidence rate ratio, shown with 95% confidence interval.

TABLE 4. Change in the Rate of Noninfectious Adverse Events After the Policy Change Based on Isolation Status

Isolation Status	Preintervention Rate <sup>a</sup> (Before n = 24,732 Admissions) <sup>b</sup>	Postintervention Rate <sup>a</sup> (After n = 25,536 Admissions) <sup>b</sup>	Decrease%	P Value <sup>c</sup>	Slope Change (95% CI) <sup>d</sup>	P Value <sup>c</sup>
No isolation	9.9	9.9	0	.99	0.94 (0.89–0.99)	<b>.03</b>
MRSA and/or VRE	21.4	6.08	72	< .001	0.84 (0.70–1.00)	<b>.49</b>

NOTE. MRSA, methicillin-resistant *Staphylococcus aureus*; VRE, vancomycin-resistant Enterococcus.

<sup>a</sup>Rates are noninfectious adverse events per 1,000 admissions.

<sup>b</sup>MRSA/VRE, 12% of admissions; non-MRSA/VRE, 88% of admissions. These denominators were used to calculate the respective rates.

<sup>c</sup>Bold values are statistically significant.

<sup>d</sup>Slope change is the incidence rate ratio (with 95% confidence interval).

Statistical analyses were performed using SAS version 9.4 software (SAS Institute, Cary, NC) and SPSS version 24 software (IBM, Armonk, NY). *P* values < .05 were considered statistically significant.

## RESULTS

Overall, there were 24,732 admissions in the preintervention period and 25,536 admissions in the postintervention period after CP discontinuation. In the preintervention period, ~12% admissions were isolated for MRSA and/or VRE, and the monthly rate remained relatively constant. No patients were isolated for MRSA/VRE in the postintervention period. Overall, 835 adverse events occurred in the preintervention period and 765 adverse events occurred in the postintervention period. The events were divided into infectious and noninfectious adverse events. The demographics of patients with adverse events are displayed in Table 2.

Noninfectious adverse events declined after CP discontinuation from 12.3 to 10.0 events per 1,000 admissions (*P* = .022), which is a 19% decrease in noninfectious adverse

events after 1 year. No statistically significant change in infectious adverse events was detected (20.7 to 19.4 adverse events per 1,000 admissions; *P* = .33) (Figure 1).

No change in the rate of hospital adverse events was observed after the intervention. The monthly incidence rate ratio for noninfectious adverse events was 1.02 per 1,000 admissions (95% CI, 0.71–1.46; *P* = .913) and for infectious adverse events, the monthly incidence rate ratio was 1.31 per 1,000 admissions (95% CI, 1.00–1.71; *P* = .051), indicating no significant change in this rate immediately after CP discontinuation.

The slope change was significant for noninfectious adverse events and demonstrated a decrease in monthly adverse events after the CP change, with an incidence rate ratio of 0.94 adverse events per 1,000 admissions (95% CI, 0.90–0.99; *P* = .028) (Figure 1). No significant slope change was observed for infectious adverse events, and the monthly incidence rate ratio was 0.99 adverse events per 1,000 admissions (95% CI, 0.95–1.02; *P* = .43).

Each adverse event in the composite end-point analysis was evaluated individually, accounting for repeated observations in




FIGURE 1. Monthly rates of infectious and noninfectious adverse events before and after contact precautions were discontinued for methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE). NOTE. CP, contact precautions; pre, with contact precautions for both MRSA and VRE; post, no contact precautions for MRSA or VRE; trend lines, slopes of the monthly incidence rate ratios for the preintervention and postintervention periods, as well as the change point for immediate effect.

the same person in the model (Table 3). Although we detected trends toward fewer falls and trauma, postoperative hemorrhage and/or hematoma, pressure ulcers, and PE/DVT, these trends were not statistically significant. Even though we observed no change in the rate of overall infectious adverse events, SSI decreased by 24% after CP were discontinued, from 5.2 to 4.0 events per 1,000 admissions ( $P=.03$ ). We detected a trend toward an increase in CLABSI, postoperative sepsis, and VAP, but these changes were small and did not reach statistical significance.

The slope change was calculated for each adverse event as well. The slope change was significant for postoperative hemorrhage and hematoma, SSI, and it indicated a decline in monthly events after the CP change for both adverse events

(Table 3). The slope change was not significant for the remaining adverse events.

No significant rate changes for any individual adverse events were observed, except for hospital onset *C. difficile* (data not shown). An initial increase in the rate of *C. difficile* occurred directly after the policy change, with an incidence rate ratio of 1.96 (95% CI, 1.23–3.14;  $P=.005$ ), but after the initial increase, the rate declined to a level similar to that observed prior to the intervention.

The CP status of each patient with a noninfectious adverse event was evaluated. When comparing patients with MRSA/VRE who were isolated in the preintervention period and not isolated in the postintervention period, a 72% decline was




FIGURE 2. Comparison of isolation status and rate of noninfectious adverse events. NOTE. CP, contact precautions; pre, with contact precautions for both methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant Enterococcus (VRE); post, no contact precautions for MRSA or VRE; trend lines, slopes of the monthly incidence rate ratios for the preintervention and postintervention periods, as well as the change point for immediate effect; MRSA/VRE, 12% of admissions; non-MRSA/VRE, 88% of admissions. Denominators: (A) based on admissions with no MRSA; (B) based on rate of admission with MRSA/VRE.

observed in noninfectious adverse events ( $P < .001$ ) (Figure 2). This rate decline was driven by falls and trauma, postoperative hemorrhage and/or hematoma, and deep vein thrombosis or pulmonary embolism, which exhibited the largest declines in this population. No significant change was observed for non-isolation patients, who remained off CP in both the pre-intervention and postintervention periods (Table 4). Patients on either “other isolation” or “combination isolation” remained in isolation for both the preintervention and post-intervention periods. The sample sizes were small (<2% of

admissions), and very few noninfectious adverse events occurred in these groups. Thus, no statistically significant changes in noninfectious adverse events occurred after CP discontinuation (data not shown).

## DISCUSSION

Controversy surrounds both the efficacy of and patient harms associated with CP. Recent data suggest that discontinuing

routine CP for MRSA and VRE can be performed without increasing healthcare-associated infections with these organisms, but whether removing CP reduces overall patient harms remains unclear.<sup>3,6–8</sup> This study demonstrated that removing routine CP for MRSA and VRE was associated with a decline in noninfectious adverse events, including falls and trauma, postoperative hemorrhage and/or hematoma, wound dehiscence, pressure ulcers, and PE/DVTs. None of the secondary end points were statistically significant, which is likely due to the low overall rates of the individual events. These data support prior research indicating that the use of CP can be a barrier to access to healthcare providers and that this can impact adverse event rates.

Importantly, the populations with the largest decline in noninfectious adverse events were the patients with MRSA and VRE, who they were no longer isolated during the post-intervention period. While this population was isolated, the average rate of noninfectious adverse events was 21.4 per 1,000 MRSA/VRE admissions, and after the policy change, the adverse event rate decreased to 6.08 per 1,000 MRSA/VRE admissions. While an argument could be made that the decline in adverse events was multifactorial and may have been due to other quality-improvement interventions, the large decline in noninfectious adverse events was observed only in the MRSA/VRE population and not in the “no isolation” group. In addition, Figure 2b shows that the decline began shortly after the policy change and that the lower rate remained months after the intervention. Also, no change in the rate was observed in the other isolation statuses, who remained in isolation in the postintervention period, but events in these populations were rare, making this aspect difficult to fully assess.

In our prior study, we showed that MRSA and VRE clinical cultures, as a marker of healthcare-associated infections, did not increase after CP discontinuation and CHG bathing was expanded to all units.<sup>6</sup> This study further demonstrates that other reportable infectious adverse events did not increase after CP were discontinued, including infections with other organisms and device-associated infections. Prior to the collection of these data, there was a theoretical concern that having fewer patients on CP could lead to increases in hospital-acquired infections, but our study results did not show an increase after the policy change. This finding may be due to the other horizontal infection prevention strategies, including near-universal CHG bathing and our high hand hygiene rate (>90%). This study also showed a significant decline in the SSI rate after the policy was changed. The reason for the improvement is unclear, and it may be related to improved access to healthcare providers, decreased microbial burden from expanded CHG bathing, or both. Further research is needed in this area.

While these initial data are encouraging, our study has some limitations. First, this study was performed at a single acute-care hospital with single-patient rooms and a high hand hygiene compliance rate (>90%).<sup>6</sup> Whether these data on infectious adverse events are generalizable to other hospitals with shared patient rooms or a lower hand hygiene rate is

unclear. Further research in other hospitals is necessary to determine the additional factors necessary for this new policy to be successful.

Our institution also has a robust quality-control department that is focused on reducing adverse events. Although no specific hospital-wide interventions occurred during this study, it is unclear whether the results are generalizable to other institutions that do not have established programs focused on reducing falls, DVTs, postsurgical adverse events, etc. To see a significant decline in noninfectious adverse events among MRSA/VRE patients, a combination of quality-improvement strategies and removal of CP may be necessary to improve outcomes. Further research in this area should be conducted.

This study was quasi-experimental; therefore, it was not possible to demonstrate causality. Although the data suggest that removing CP and expanding CHG bathing contributed to a decline in noninfectious adverse events, further research is necessary with a more robust study design, such as a prospective, randomized control trial or a cross-over study.

To determine the composite end points, our team reviewed the list of all reportable events and selected the events with a plausible link to healthcare worker contact time. Although our team considered this list thoughtfully, it is unclear how many of these events were truly due to lack of healthcare contact, given that the amount of time each spent with their providers was not evaluated in this study. These events, in general, are all likely multifactorial, and contact with providers is likely just 1 factor.

The data used were also collected for public reporting and not specifically for research or patient care. While these findings may be generalizable to other hospitals that report based on the same definitions, the data were collected based on reporting criteria and may not have captured all actual events. However, this limitation likely impacted both the pre-intervention and postintervention periods equally because the definitions were relatively constant, except for CAUTI, which was not statistically significant.

To determine which patients would have qualified for MRSA/VRE in the postintervention period, we used specific criteria that would have triggered an isolation alert in the preintervention period. This approach has some limitations. First, it is possible that a patient had history of MRSA/VRE from another hospital that would have been missed in the postintervention period, but this group likely represents only a small portion of the MRSA/VRE population. It is also possible that some VRE patients may have been missed, given that routine screening was no longer performed in the postintervention period (1.3% of patients were VRE screen positive in the preintervention period). However, given the California mandate, MRSA screening was continued in the postintervention period, so our data are likely reasonably accurate. Although incorrect isolation status is a concern, only a small portion of cases would have been affected. Even if patients were missed, the overall rate of noninfectious adverse events did decline.

This study showed that 1 year after discontinuing routine CP for endemic MRSA and VRE and expanding CHG bathing,

a significant decline in noninfectious adverse events occurred, with the largest decline in patients who no longer required isolation for MRSA and VRE. Also, no increase in infectious adverse events was observed, including device-associated infections. These data and prior data indicating that the removal of routine CP can be performed without an increase in infectious complications suggest that the removal of MRSA/VRE CP can contribute to improved patient safety and reduction of preventable adverse events.<sup>6–8</sup> More data on the optimal hospital conditions and quality improvement programs are needed to make this intervention successful. Given that CP are likely still necessary for specific populations, strategies to increase contact with healthcare providers and decrease noninfectious adverse events in these patients should be developed.

#### ACKNOWLEDGMENTS

*Financial support:* The study was self-funded. No financial support was provided relevant to this article. Statistical collaboration was supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI (grant no. UL1TR001881).

*Potential conflicts of interest:* All authors report no conflicts of interest relevant to this article.

Address correspondence to Elise Martin, MD, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 LeConte Ave, 37-121 CHS, Los Angeles, CA 90095 (emartin@mednet.ucla.edu).

#### REFERENCES

1. Calfee DP, Salgado CD, Milstone AM, et al. Strategies to prevent methicillin-resistant *Staphylococcus aureus* transmission and infection in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol* 2014;35:772–796.
2. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of *Staphylococcus aureus* and Enterococcus. *Infect Control Hosp Epidemiol* 2003;24:362–386.
3. Morgan DJ, Murthy R, Munoz-Price LS, et al. Reconsidering contact precautions for endemic methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant Enterococcus. *Infect Control Hosp Epidemiol* 2015;36:1163–1172.
4. Fatkenheuer G, Hirschel B, Harbarth S. Screening and isolation to control methicillin-resistant *Staphylococcus aureus*: sense, nonsense, and evidence. *Lancet* 2015;385:1146–1149.
5. Morgan DJ, Kaye KS, Diekema DJ. Reconsidering isolation precautions for endemic methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant Enterococcus. *JAMA* 2014;312:1395–1396.
6. Martin EM, Russell D, Rubin Z, et al. Elimination of routine contact precautions for endemic methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant Enterococcus: a retrospective quasi-experimental study. *Infect Control Hosp Epidemiol* 2016;37:1323–1330.
7. Edmond MB, Masroor N, Stevens MP, Ober J, Bearman G. The impact of discontinuing contact precautions for VRE and MRSA on device-associated infections. *Infect Control Hosp Epidemiol* 2015;36:978–980.
8. McKinnell JA, Eells SJ, Clark E, et al. Discontinuation of contact precautions with the introduction of universal daily chlorhexidine bathing. *Epidemiol Infect* 2017;145:2575–2581.
9. Bearman GM, Marra AR, Sessler CN, et al. A controlled trial of universal gloving versus contact precautions for preventing the transmission of multidrug-resistant organisms. *Am J Infect Control* 2007;35:650–655.
10. Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. *Lancet Infect Dis* 2014;14:31–39.
11. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant *Staphylococcus aureus* at hospital admission and nosocomial infection in surgical patients. *JAMA* 2008;299:1149–1157.
12. Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. *JAMA* 2013;310:1571–1580.
13. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2006;43:971–978.
14. Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. *N Engl J Med* 2011;364:1407–1418.
15. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant *Staphylococcus aureus* infections. *N Engl J Med* 2011;364:1419–1430.
16. Lucet JC, Paoletti X, Lolom I, et al. Successful long-term program for controlling methicillin-resistant *Staphylococcus aureus* in intensive care units. *Intensive Care Med* 2005;31:1051–1057.
17. Marshall C, Richards M, McBryde E. Do active surveillance and contact precautions reduce MRSA acquisition? A prospective interrupted time series. *PLoS One* 2013;8:e58112.
18. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant *Staphylococcus aureus* in 3 affiliated hospitals. *Ann Intern Med* 2008;148:409–418.
19. Safdar N, Marx J, Meyer NA, Maki DG. Effectiveness of pre-emptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant *Staphylococcus aureus* in a burn unit. *Am J Infect Control* 2006;34:476–483.
20. De Angelis G, Cataldo MA, De Waure C, et al. Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. *J Antimicrob Chemother* 2014;69:1185–1192.
21. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. *JAMA* 2003;290:1899–1905.
22. Karki S, Leder K, Cheng AC. Patients under contact precautions have an increased risk of injuries and medication errors: a retrospective cohort study. *Infect Control Hosp Epidemiol* 2013;34:1118–1120.
23. Reed CR, Ferguson RA, Peng Y, et al. Contact isolation is a risk factor for venous thromboembolism in trauma patients. *J Trauma Acute Care Surg* 2015;79:833–837.
24. Dashiell-Earp CN, Bell DS, Ang AO, Uslan DZ. Do physicians spend less time with patients in contact isolation? A time-motion study of internal medicine interns. *JAMA Intern Med* 2014;174:814–815.

25. Evans HL, Shaffer MM, Hughes MG, et al. Contact isolation in surgical patients: A barrier to care? *Surgery* 2003;134:180–188.
26. Masse V, Valiquette L, Boukhoudmi S, et al. Impact of methicillin-resistant *Staphylococcus aureus* contact isolation units on medical care. *PLoS One* 2013;8:e57057.
27. Morgan DJ, Pineles L, Shardell M, et al. The effect of contact precautions on healthcare worker activity in acute care hospitals. *Infect Control Hosp Epidemiol* 2013;34:69–73.
28. Saint S, Higgins LA, Nallamothu BK, Chenoweth C. Do physicians examine patients in contact isolation less frequently? A brief report. *Am J Infect Control* 2003;31:354–356.
29. Gilligan P, Quirke M, Winder S, Humphreys H. Impact of admission screening for methicillin-resistant *Staphylococcus aureus* on the length of stay in an emergency department. *J Hosp Infect* 2010;75:99–102.
30. McLemore A, Bearman G, Edmond MB. Effect of contact precautions on wait time from emergency room disposition to inpatient admission. *Infect Control Hosp Epidemiol* 2011;32:298–299.
31. Goldszer RC, Tamplin E, Yokoe DS, et al. A program to remove patients from unnecessary contact precautions. *J Clin Outcome Manage* 2002;9:553–556.
32. Tran K, Bell C, Stall N, et al. The effect of hospital isolation precautions on patient outcomes and cost of care: a multi-site, retrospective, propensity score-matched cohort study. *J Gen Intern Med* 2017;32:262–268.
33. Day HR, Morgan DJ, Himelhoch S, Young A, Perencevich EN. Association between depression and contact precautions in veterans at hospital admission. *Am J Infect Control* 2011;39:163–165.
34. Mehrotra P, Croft L, Day HR, et al. Effects of contact precautions on patient perception of care and satisfaction: a prospective cohort study. *Infect Control Hosp Epidemiol* 2013;34:1087–1093.
35. Croft LD, Liquori M, Ladd J, et al. The effect of contact precautions on frequency of hospital adverse events. *Infect Control Hosp Epidemiol* 2015;36:1268–1274.
36. Croft LD, Harris AD, Pineles L, et al. The effect of universal glove and gown use on adverse events in intensive care unit patients. *Clin Infect Dis* 2015;61:545–553.
37. Patient safety indicators overview. Agency for Healthcare Research and Quality website. [http://www.qualityindicators.ahrq.gov/modules/psi\\_overview.aspx](http://www.qualityindicators.ahrq.gov/modules/psi_overview.aspx). Accessed January 17, 2017.
38. Hospital-acquired conditions. Centers for Medicare and Medicaid Services website. [https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitalacqcond/hospital-acquired\\_conditions.html](https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitalacqcond/hospital-acquired_conditions.html). Published 2015. Accessed January 17, 2017.
39. National Healthcare Safety Network (NHSN) patient safety component manual. Centers for Disease Control and Prevention website. [https://www.cdc.gov/nhsn/pdfs/validation/2017/pcsmanual\\_2017.pdf](https://www.cdc.gov/nhsn/pdfs/validation/2017/pcsmanual_2017.pdf). Published 2017. Accessed April 5, 2018.
40. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Therapeut* 2002;27:299–309.